Metsera (NASDAQ:MTSR) Receives Sell (D) Rating from Weiss Ratings

Key Points

• Weiss Ratings has restated its "sell (d)" rating for Metsera (NASDAQ:MTSR), reflecting ongoing concerns about the company's performance.
• Wells Fargo & Company downgraded Metsera from "overweight" to "equal weight" with a target price of $54.00, while Bank of America raised its target price from $45.00 to $50.00 and maintained a "buy" rating.
• Metsera is a clinical stage biopharmaceutical company focused on developing hormone analog peptides for conditions related to obesity and overweight, with several products in its pipeline.

Metsera (NASDAQ:MTSR - Get Free Report)'s stock had its "sell (d)" rating restated by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Several other brokerages also recently weighed in on MTSR. Wells Fargo & Company downgraded shares of Metsera from an "overweight" rating to an "equal weight" rating and set a $54.00 target price for the company. in a research note on Tuesday, September 30th. Cantor Fitzgerald reissued an "overweight" rating on shares of Metsera in a research note on Wednesday, September 3rd. Wall Street Zen raised shares of Metsera from a "sell" rating to a "hold" rating in a research note on Wednesday, October 1st. Leerink Partnrs downgraded shares of Metsera from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 24th. Finally, Bank of America boosted their target price on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 28th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Metsera presently has a consensus rating of "Hold" and a consensus target price of $55.75.

Metsera Stock Down 0.1%

NASDAQ:MTSR opened at $52.84 on Wednesday. Metsera has a 52-week low of $12.30 and a 52-week high of $54.47. The stock has a fifty day simple moving average of $38.58 and a 200-day simple moving average of $31.43.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Alphabet Inc. purchased a new stake in shares of Metsera during the 1st quarter worth about $135,059,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Metsera during the 1st quarter worth about $78,748,000. Wellington Management Group LLP purchased a new stake in shares of Metsera during the 1st quarter worth about $65,382,000. Alpha Wave Global LP purchased a new stake in shares of Metsera during the 1st quarter worth about $64,894,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Metsera during the 1st quarter worth about $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.